Zevra Therapeutics will present at the Piper Sandler Healthcare Conference on December 2, 2026, and offers one-on-one meetings.
Quiver AI Summary
Zevra Therapeutics, Inc. announced that its executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York on December 2, 2026, at 1:00 p.m. ET, with opportunities for one-on-one meetings for attendees. The company is dedicated to developing life-changing therapies for rare diseases and is currently focused on expanding access and advancing its late-stage pipeline. They highlight the successful commercialization of their lead product for Niemann-Pick disease type C as foundational to their strategy. Zevra emphasizes its commitment to patient-centric values and acknowledges the risks associated with forward-looking statements regarding their future performance. For more details, interested parties can visit Zevra's website.
Potential Positives
- Zevra Therapeutics will present at a prominent healthcare conference, increasing visibility and engagement in the industry.
- Management's availability for one-on-one meetings with attendees enhances networking opportunities and potential partnerships.
- The company's commitment to broadening access and progressing its late-stage pipeline signals potential growth and impact in treating rare diseases.
- The successful commercialization of their lead product for Niemann-Pick disease validates their strategic execution and market capability.
Potential Negatives
- The press release includes cautionary language about forward-looking statements, indicating uncertainty and potential risks that may adversely affect the company's future performance.
- There is an implicit acknowledgment of the need to seek geographic expansion and progress key milestones, suggesting that current operations may not be sufficient for growth or stability.
- No concrete updates on the current status or progress of its late-stage pipeline are provided, which may raise concerns among investors about the company's immediate prospects.
FAQ
When will Zevra Therapeutics present at the Piper Sandler conference?
Zevra Therapeutics will present on December 2, 2026, at 1:00 p.m. ET.
Where can I watch the live webcast of the presentation?
The live webcast can be accessed on the "Events & Presentations" page in Zevra's Investor Relations section.
What is the focus of Zevra Therapeutics?
Zevra Therapeutics is focused on bringing life-changing therapies to people living with rare diseases.
What is Zevra's lead product for?
Zevra's lead product is marketed in the U.S. for Niemann-Pick disease type C, a rare, progressive neurodegenerative disease.
Who can I contact for investor inquiries at Zevra?
For investor inquiries, you can contact Nichol Ochsner at +1 (732) 754-2545 or via email.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZVRA Insider Trading Activity
$ZVRA insiders have traded $ZVRA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ZVRA stock by insiders over the last 6 months:
- RAHSAAN THOMPSON (Chief Legal & Compliance) has made 0 purchases and 2 sales selling 77,223 shares for an estimated $913,078.
- NEIL F. MCFARLANE (President and CEO) sold 20,000 shares for an estimated $224,948
- COREY MICHAEL WATTON sold 12,300 shares for an estimated $138,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ZVRA Revenue
$ZVRA had revenues of $37.8M in Q3 2026. This is an increase of 44.86% from the same period in the prior year.
You can track ZVRA financials on Quiver Quantitative's ZVRA stock page.
You can access data on ZVRA stock through the Quiver Quantitative API.
$ZVRA Hedge Fund Activity
We have seen 107 institutional investors add shares of $ZVRA stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $17,208,000
- POINT72 ASSET MANAGEMENT, L.P. removed 1,157,131 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $16,593,258
- INTEGRITY ALLIANCE, LLC. added 938,167 shares (+inf%) to their portfolio in Q3 2026, for an estimated $10,291,691
- KINGDON CAPITAL MANAGEMENT, L.L.C. removed 775,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $8,501,750
- FMR LLC added 647,064 shares (+13.2%) to their portfolio in Q3 2026, for an estimated $7,098,292
- QUBE RESEARCH & TECHNOLOGIES LTD removed 525,207 shares (-42.3%) from their portfolio in Q3 2026, for an estimated $5,761,520
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 480,343 shares (+80.4%) to their portfolio in Q3 2026, for an estimated $5,269,362
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ZVRA Analyst Ratings
Wall Street analysts have issued reports on $ZVRA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/16/2026
- Cantor Fitzgerald issued a "Overweight" rating on 11/13/2026
- BTIG issued a "Buy" rating on 11/13/2026
- HC Wainwright & Co. issued a "Buy" rating on 08/20/2026
- Citizens issued a "Market Outperform" rating on 08/06/2026
- Canaccord Genuity issued a "Buy" rating on 07/27/2026
To track analyst ratings and price targets for $ZVRA, check out Quiver Quantitative's $ZVRA forecast page.
$ZVRA Price Targets
Multiple analysts have issued price targets for $ZVRA recently. We have seen 8 analysts offer price targets for $ZVRA in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Eddie Hickman from Guggenheim set a target price of $18.0 on 11/16/2026
- Kambiz Yazdi from BTIG set a target price of $21.0 on 11/13/2026
- Kristen Kluska from Cantor Fitzgerald set a target price of $19.0 on 11/13/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $26.0 on 08/20/2026
- Jason N. Butler from Citizens set a target price of $28.0 on 08/06/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $20.0 on 07/27/2026
- Jason McCarthy from Maxim Group set a target price of $35.0 on 06/10/2026
Full Release
BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the Piper Sandler 38 th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 1:00 p.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “ Events & Presentations ” page in the Investor Relations section of Zevra’s website at investors.zevra.com .
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn .
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 3, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
[email protected]
Media Contact
Julie Downs
+1 (508) 246-3230
[email protected]